Actively Recruiting
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Led by Therini Bio Pty Ltd · Updated on 2024-12-19
21
Participants Needed
2
Research Sites
62 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
CONDITIONS
Official Title
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to understand study procedures and risks and provide written informed consent before starting
- Age between 18 and 80 years inclusive at the time of consent
- Diagnosis of diabetic macular edema
- Vision loss in the study eye
You will not qualify if you...
- Pregnant or breastfeeding
- Cataract surgery or any other eye surgery in the study eye within 3 months before screening
- Any other condition besides diabetic macular edema that could affect study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Marsden Eye Specialists
Parramatta, New South Wales, Australia, 2150
Actively Recruiting
2
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Not Yet Recruiting
Research Team
L
Liza Wallace
CONTACT
J
Joel Naor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here